ExogenusTherapeutics

Exogenus Therapeutics is a biotechnology company based in Cantanhede, Portugal, focused on developing multifactorial, disease-modifying biologics for regenerative medicine. The company works with extracellular vesicles and other nanoparticles, seeking to translate their therapeutic potential into treatments for significant healthcare needs. Its lead programme, Exo-101, is an extracellular-vesicle-enriched secretome in development for knee osteoarthritis. Exogenus is also exploring potential applications in cisplatin-induced hearing loss and other regenerative medicine indications.

The company’s work spans research and development, from scientific discovery through clinical development, and includes advancing its technology, pipeline and intellectual property. Exogenus supports innovation through collaborative R&D, partnering with others to combine expertise and accelerate development. Its activities include developing new therapeutic candidates and working on manufacturing processes, including GMP-compliant production for Exo-101. The company also shares scientific knowledge through publications and communicates updates on its research, partnerships and pipeline. Guided by scientific rigour, collaboration and responsible innovation, Exogenus Therapeutics aims to advance new biologic therapies for patients.